JOURNAL OF THE CZECH PEDIATRIC SOCIETY AND THE SLOVAK PEDIATRIC SOCIETY

Čes-slov Pediat 2025, 80(Suppl.1):24-29 | DOI: 10.55095/CSPediatrie2025/023

Epidemiology of invasive pneumococcal diseases in relation to vaccination options in children in the Czech Republic

Jan Smetana
Katedra epidemiologie, Vojenská lékařská fakulta, Univerzita obrany, Hradec Králové

The incidence of invasive pneumococcal disease (IPD) depends on age, the presence of chronic diseases and other risk factors. Young children under 4 years of age are among

the most at risk age groups. In the Czech Republic (CZ), pneumococcal diseases are a significant cause of morbidity and mortality in children. In 2023, the recorded morbidity rate was 4.4/100,000 in the 0-11 months age group and 7.1/100,000 in the 1-4 years age group. In 2020-2023, 4 children died in the 0-4 years age group in the CZ. Voluntary, fully-funded vaccination of children, including

selected health-risk groups, is currently in place in the CZ. The recommended and covered vaccines are 20/15/13 valent conjugate vaccines. The preferred vaccines for childhood vaccination are PCV20 and PCV15. Vaccination coverage with at least one dose of some vaccine was reported to be 76.4% for children born in 2022. With the increasing numbers of pneumococcal serotypes in vaccines, the

theoretical coverage and prevention of IPD cases is increasing. In 2019-2023, the theoretical coverage of IPD cases in the 0-11 months age group would be 38% for PCV13, 45% for PCV15 and 62% for PCV20. The most common pneumococcal serotypes in IPD cases in 2023 in the CZ were 3, 19A and 8. Serotypes 3 and 19A are included in all recommended conjugate vaccines (PCV20, PCV15, PCV13). Serotype 8 is

included and therefore potentially covered only in PCV20. To achieve the maximum benefit of vaccination in children, the earliest possible vaccination is the most optimal.

Keywords: invasive pneumococcal disease, epidemiology, children, vaccination, reimbursement

Accepted: April 10, 2025; Published: August 1, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Smetana J. Epidemiology of invasive pneumococcal diseases in relation to vaccination options in children in the Czech Republic. Ces-slov Pediat. 2025;80(Suppl.1):24-29. doi: 10.55095/CSPediatrie2025/023.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. . Blechová Z. Pneumokokové infekce v dětském věku. Pediatr Praxi 2006; 2: 91-95.
    2. . CDC. Clinical overview of pneumococcal disease. Dostupné na: https://www.cdc.gov/pneumococcal/hcp/clinical-overview/index.html. ECDC. Invasive pneumococcal disease. Annual epidemiological report for 2022. Dostupné na: https://www.ecdc.europa.eu/en/publications-data/invasive-pneumococcal-disease-annual-epidemiological-report-2022
    3. . Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 2004; 4(3): 144-154. Go to original source... Go to PubMed...
    4. . ECDC. Factsheet for health professionals about pneumococcal disease. Dostupné na: https://www.ecdc.europa.eu/en/pneumococcal-disease/facts
    5. . Thomas RE. Pneumococcal pneumonia and invasive pneumococcal disease in those 65 and older: rates of detection, risk factors, vaccine effectiveness, hospitalisation and mortality. Geriatrics 2021; 6(1): 13. Go to original source... Go to PubMed...
    6. . WHO. WHO position paper on pneumococcal conjugate vaccines in infants and children under 5 years of age - February 2019. Weekly Epidemiological Record 2019; 94(8): 85-104. Dostupné na: https://cdn.who.int/media/docs/default-source/immunization/position_paper_documents/pneumococcus/who-pp-pcv-2019-presentation.pdf?sfvrsn=e054efe1_2
    7. . Kozáková J, Vohrnová S, Okonji Z, et al. Invazivní pneumokoková onemocnění v České republice v roce 2023. Zprávy CEM (SZU, Praha). 2024; 33(6): 193-197.
    8. . Kozáková J, Žemličková H, Vohrnová S, et al. Invazivní pneumokokové onemocnění v České republice v roce 2022. Zprávy CEM (SZU, Praha). 2023; 32(6-7): 261-626.
    9. . Kozáková J, Žemličková H, Vohrnová S, et al. Invazivní pneumokokové onemocnění v České republice v roce 2021 (Druhý rok ovlivněný pandemií covid-19). Zprávy CEM (SZU, Praha) 2022; 31(6): 217-221.
    10. . Kozáková J, Okonji Z, Vohrnová S, et al. Invazivní pneumokokové onemocnění v České republice v roce 2020 (Ovlivnila pandemie covid-19 situaci ve výskytu IPO v ČR?). Zprávy CEM (SZU, Praha) 2021; 30(4): 115-120.
    11. . Musher DM, Anderson R, Feldman C. The remarkable history of pneumococcal vaccination: an ongoing challenge. Pneumonia 2022; 14(1): 5. Go to original source... Go to PubMed...
    12. . Balsells E, Guillot L, Nair H, et al. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis. PLoS One 2017; 12(5): e0177113. Go to original source... Go to PubMed...
    13. . Amin-Chowdhury Z, Collins S, Sheppard C, et al. Characteristics of invasive pneumococcal disease caused by emerging serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine in England: A prospective observational cohort study, 2014-2018. Clin Infect Dis 2020; 71(8): e235-e243. Go to original source... Go to PubMed...
    14. . Garcia Quesada M, Yang Y, Bennett JC, et al. Serotype distribution of remaining pneumococcal meningitis in the mature PCV10/13 period: Findings from the PSERENADE project. Microorganisms 2021; 9(4): 738. Go to original source... Go to PubMed...
    15. . Levy C, Varon E, Ouldali N, et al. Bacterial causes of otitis media with spontaneous perforation of the tympanic membrane in the era of 13 valent pneumococcal conjugate vaccine. PLoS One 2019; 14(2): e0211712. Go to original source... Go to PubMed...
    16. . Ekinci E, Desmet S, Van Heirstraeten L, et al. Streptococcus pneumoniae serotypes carried by young children and their association with acute otitis media during the period 2016-2019. Front Pediatr 2021; 9: 664083. Go to original source... Go to PubMed...
    17. . Morales M, Ludwig G, Ercibengoa M, et al. Changes in the serotype distribution of Streptococcus pneumoniae causing otitis media after PCV13 introduction in Spain. PLoS One 2018; 13(12): e0209048. Go to original source... Go to PubMed...
    18. . Kaur R, Fuji N, Pichichero ME. Dynamic changes in otopathogens colonizing the nasopharynx and causing acute otitis media in children after 13-valent (PCV13) pneumococcal conjugate vaccination during 2015-2019. Eur J Clin Microbiol Infect Dis 2022; 41(1): 37-44. Go to original source... Go to PubMed...
    19. . Müller A, Kleynhans J, de Gouveia L, et al. Streptococcus pneumoniae serotypes associated with death, South Africa, 2012-2018. Emerg Infect Dis 2022; 28(1): 166-179. Go to original source... Go to PubMed...
    20. . De Miguel S, Latasa P, Yuste J, et al. Age-dependent serotype-associated case-fatality rate in invasive pneumococcal disease in the autonomous community of Madrid between 2007 and 2020. Microorganisms 2021; 9(11): 2286. Go to original source... Go to PubMed...
    21. . Yun KW, Rhie K, Kang JH, et al. Emergence of serotype 10A-ST11189 among pediatric invasive pneumococcal diseases, South Korea, 2014-2019. Vaccine 2021; 39(40): 5787-5793. Go to original source... Go to PubMed...
    22. . Ouldali N, Cohen R, Levy C, et al. Pneumococcal susceptibility to antibiotics in carriage: a 17 year time series analysis of the adaptive evolution of non-vaccine emerging serotypes to a new selective pressure environment. J Antimicrob Chemother 2019; 74(10): 3077-3086. Go to original source... Go to PubMed...
    23. . Rozenbaum MH, Huang L, Perdrizet J, et al. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants. Vaccine 2024; 42(3): 573-582. Go to original source... Go to PubMed...
    24. . Česká vakcinologická společnost ČLS JEP. Doporučení České vakcinologické společnosti ČLS JEP pro očkování dětí a adolescentů ve věku 0-17 let proti pneumokokovým onemocněním, 10. dubna 2024. Dostupné na: https://www.vakcinace.eu/doporuceni-a-stanoviska
    25. . Zákon č. 48/1997 Sb., o veřejném zdravotním pojištění, § 30 Hrazené služby. Dostupné na: https://www.zakonyprolidi.cz/cs/1997-48#Top
    26. . Ministerstvo zdravotnictví České republiky. Sdělení Ministerstva zdravotnictví č. 23/2024 z 29. 1. 2024 o antigenním složení očkovacích látek proti pneumokokovým infekcím pro očkování v dětském věku a u pojištěnců s rizikovými faktory zdravotního stavu. Dostupné na: https://www.zakonyprolidi.cz/cs/2024-23
    27. . Metodický postup k vykazování očkování od 14. 11. 2024. Dostupné na: https://www.vzp.cz/poskytovatele/informace-pro-praxi/ockovani/metodicky-postup-k-vykazovani-ockovani
    28. . Národní zdravotnický informační portál. Očkování v dostupných datech. Dostupné na: https://www.nzip.cz/data/1704-ockovani-v-dostupnych-datech-nzis, staženo 4. 2. 2025

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content